Right now, the testing's been done on unaccinated people who are at risk of. high risk of more severe outcomes from coded that is going to change. They're going to test these pills on people who are vaccinated, d have break trough cases. And they will also continue to test them a sort of, a, like a adjusting case druk,. Like if you had someone in your household got quilted, you might take these pills to prevent yourself from getting qoted in the first place. So there is big potential market here, but the early stage of getting the coted diagnosis and getting these pills really quickly, that's key.
Dr. Ian Lustbader, Clinical Professor of Medicine at NYU Langone, discusses why the shot-or-test rule makes sense. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Cynthia Koons explain why Covid pills may save lives, but they won’t end the pandemic. Bloomberg News Health Editor John Lauerman talks about Johnson & Johnson's plan to split off its consumer division, following in the footsteps of other big drugmakers that have moved to focus on the more-profitable pharmaceutical market. Kathy Kraninger, VP of Regulatory Affairs at Solidus Labs, shares her thoughts on crypto manipulation and regulation. And We Drive to the Close with Bill Smead, CIO at Smead Capital Management.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.